52 filings
Page 2 of 3
8-K
lvcvywkm iyjllg6f90u
2 Nov 23
Termination of a Material Definitive Agreement
4:17pm
8-K
tfcuzfgde4bd7pc
16 Oct 23
Zymeworks Announces New Director Nominee
4:45pm
8-K
odf6dd5 gf0vwa6h
21 Sep 23
Termination of a Material Definitive Agreement
4:21pm
8-K
gkjxlj2msp27mrpzn ij
10 Aug 23
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:08pm
8-K
kudoz5irxmo54k7vif
29 Jun 23
Zymeworks Appoints New Director
4:12pm
8-K
75tn5
12 Jun 23
Material Modifications to Rights of Security Holders
4:06pm
8-K
qfk7o wjjse09mcm2
2 Jun 23
Other Events
7:48pm
8-K
a8f6h85i bi6yi8
18 May 23
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
8:40am
8-K
gbd6xfagdq3l
16 May 23
Entry into a Material Definitive Agreement
8:30am
8-K
e2lro5i
8 May 23
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:13pm
8-K
8rrqj6 k7
26 Apr 23
Entry into a Material Definitive Agreement
8:30am
8-K
rb5d6a4fftauq1y9
18 Apr 23
ZW191 demonstrates strong responses in FRĪ±-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles
4:18pm
8-K
p8ddzm mx6
10 Apr 23
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
4:46pm
8-K
ap237jkz4k2vu
17 Mar 23
Termination of a Material Definitive Agreement
4:16pm
8-K
zt3o3g
15 Mar 23
Amendments to Articles of Incorporation or Bylaws
4:16pm
8-K
5fc6kxdn3t lm8uc
7 Mar 23
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
4:06pm
8-K
q2vt vm8y8wrw6e
19 Jan 23
Other Events
8:11am
8-K
6acuntj0c
4 Jan 23
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
4:21pm
8-K
crm92w2d1h
30 Dec 22
Departure of Directors or Certain Officers
4:31pm
8-K
u3t9iiy1pg8s ia5axp0
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
8:37am